| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
SR-19881 targets estrogen-related receptors ERRγ and ERRβ, which are orphan nuclear receptors that serve as key regulators of cellular energy homeostasis, mitochondrial function, and transcriptional programs linked to metabolism. It is a potent dual agonist of ERRγ and ERRβ with EC₅₀ values of 0.39 and 0.63 μM, respectively.
|
|---|---|
| ln Vitro |
In vitro, SR-19881 is a potent dual agonist of ERRγ and ERRβ. It has an EC₅₀ value of 0.39 μM in a binding assay and an EC₅₀ value of 4.7 μM in a cell-based assay for ERRγ. It also acts as an agonist of ERRβ with an EC₅₀ of 0.63 μM.
|
| ln Vivo |
In vivo data for SR-19881 are limited in the available literature. As a dual agonist of ERRγ and ERRβ, the compound may have potential for research in metabolic disorders, energy homeostasis, and mitochondrial function. Further in vivo studies are needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
SR-19881's receptor binding activity has been characterized for ERRγ and ERRβ. Binding assays typically involve measuring the displacement of radiolabeled ligands or using fluorescence-based assays. The compound has an EC₅₀ of 0.39 μM for ERRγ in binding assays and 0.63 μM for ERRβ.
|
| Cell Assay |
In vitro cell experiments with SR-19881 involve treating cells expressing ERRγ or ERRβ with the compound and measuring receptor activity using reporter gene assays. The compound has an EC₅₀ of 4.7 μM for ERRγ in cell-based assays. Its effects on metabolic gene expression and mitochondrial function can be assessed.
|
| Animal Protocol |
In vivo animal studies with SR-19881 have not been extensively reported in the available literature. The compound is primarily used for in vitro research. Further studies are needed to evaluate its in vivo efficacy, pharmacokinetics, and safety in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to SR-19881 are limited in the available literature. As a small molecule with a molecular weight of 312.41, the compound is expected to have reasonable bioavailability. The compound is stored at -20°C and is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
SR-19881 is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices with appropriate precautions.
|
| Additional Infomation |
SR-19881 is a potent dual agonist of ERRγ and ERRβ, with EC₅₀ values of 0.39 and 0.63 μM, respectively. It functions as a full agonist of ERRγ with an EC₅₀ of 0.39 μM in binding assays and 4.7 μM in cell-based assays. It has a CAS number of 2213490-89-0.
|
| Molecular Formula |
C19H24N2O2
|
|---|---|
| Molecular Weight |
312.406064987183
|
| Exact Mass |
312.183
|
| CAS # |
2213490-89-0
|
| PubChem CID |
145978085
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
341
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CC)C1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)O
|
| InChi Key |
BECNZUWIKCKMJG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H24N2O2/c1-3-21(4-2)17-9-5-15(6-10-17)13-14-20-19(23)16-7-11-18(22)12-8-16/h5-12,22H,3-4,13-14H2,1-2H3,(H,20,23)
|
| Chemical Name |
N-[2-[4-(diethylamino)phenyl]ethyl]-4-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2009 mL | 16.0046 mL | 32.0092 mL | |
| 5 mM | 0.6402 mL | 3.2009 mL | 6.4018 mL | |
| 10 mM | 0.3201 mL | 1.6005 mL | 3.2009 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
